

# MENINGOCOCCAL BURDEN OF DISEASE IN ARGENTINA: 10 YEARS EPIDEMIOLOGIC REVIEW




http://tago.ca/\_idw15

#2047

Analía Urueña<sup>1</sup>, Silvina Neyro<sup>2</sup>, Adriana Efron<sup>3</sup>, María E. Pannunzio<sup>4</sup>, María B. Seoane<sup>4</sup>, Jorge A. Gomez<sup>4</sup>, Norberto Giglio<sup>5</sup>

1. Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles. Universidad Isalud. Buenos Aires, Argentina; 2. Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, Argentina; 3. Servicio de Bacteriología Clínica, Instituto de Enfermedades Infecciosas-ANLIS "Dr. Carlos G. Malbrán", Buenos Aires, Argentina; 4. GSK, Buenos Aires, Argentina; 5. Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina


## BACKGROUND



Up to 2015, between 170 and 300 cases of invasive meningococcal disease (IMD) were reported in Argentina per year.<sup>1,2</sup>



In 2017, vaccination against meningococcal serogroups A, C, W and Y (MenACWY) was implemented for infants (aged 3-5 and 15 months) and adolescents (aged 11 years).




Serogroups B and W predominated in recent years.<sup>1,3</sup>

**Aim**

To update data on **IMD case numbers, incidence, mortality, CFR** and **serogroup distribution** in **Argentina** between **2010** and **2019**, and to support assessment of **prevention strategies**.




## METHODS



**Retrospective observational study** using **surveillance data** in **Argentina, 2010-2019**, including:



**IMD cases notified** to National Surveillance System\* or National Reference Laboratory as **suspicious** or **confirmed** IMD<sup>4,5</sup>




**Hospitalizations and deaths reported** by DEIS with **code** ICD-10 A39 and subcodes<sup>6</sup>


\*versions SNVS (SIVILA/C2) / SNVS2.0

## RESULTS


**IMD incidence peaked in 2013** at 0.69 per 100,000 population and declined to 0.22-0.23 per 100,000 in 2018 and 2019 (Source: DiCEI-SIISA-Malbrán Institute. Ministry of Health)




**IMD incidence declined with age** in all years and was **lowest** in **2018** and **2019** (Source: DiCEI-SIISA-Malbrán Institute. Ministry of Health)



**MenB** accounted for an **increasing proportion** of characterized serogroups in **infants aged < 1 year** (Source: DiCEI-SIISA-Malbrán Institute. Ministry of Health)



**CFR increased with age**. However, **mortality was 18 times higher in infants aged <1 year than all other age groups** (Source: DEIS. Ministry of Health)



## CONCLUSIONS

IMD burden is concentrated in **infants aged < 1 year** in Argentina with no adolescent peak

**Serogroup B** has recently become the **predominant** serogroup identified, specially in infants aged <1 year

These results show the **dynamism** of IMD, the importance of **vaccinating** at an **early age** and offering **protection** against **predominant serogroups**.

**Abbreviations:** DEIS, Directorate of Health Statistics and Information; ICD-10, International Classification of Diseases 10th Revision; IMD, invasive meningococcal disease; MenB, meningococcal serogroup B

**Funding:** GlaxoSmithKline Biologicals SA (GSK study identifier: VE0-000225); **Acknowledgments:** Business & Decision Life Sciences c/o GSK